3.2. Chemistry
Starting benzophenone analogues of uracil and thymine
1b, 1c, 1e and
1f were synthesized according to the published protocol [
10], and benzophenone derivatives of 6-methyluracil as described earlier [
20].
3.2.1. General Method for the Synthesis of Ethyl Ester of [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acids 4a–4g
A mixture of the 1-[2-(2-benzoylphenoxy)ethyl]uracil derivative 1 (1.69 mmol) and K2CO3 (0.3 g; 2.17 mmol) was stirred in DMF (10 mL) at 80 °C during 1 h. and then cooled to room temperature. Then ethyl bromoacetate was added (0.2 mL; 1.80 mmol). The resulting mixture was stirred for 20 h at room temperature. Then the reaction mixture was evaporated in vacuo, the residue was treated with 50 mL of cold water and extracted with 1,2-dichloroethane (5 × 20 mL). The extract was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with ethyl acetate. The fractions containing the product were crystallized from ethyl acetate-hexane. The yield of target esters 4a–4g was in the range of 77–89%. Compound 4e was obtained as a viscous oil with a yield of 74%.
Ethyl ester of [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (
4a). Purified by crystallization from an ethyl acetate-hexane (2:1) mixture in 90% yield. Mp 150–151 °C, R
f 0.68 (ethyl acetate:1,2-dichloroethane, 1:1).
1H-NMR (DMSO-d
6): 1.15 (3H, t,
J = 7.0 Hz, CH
3), 1.89 (3H, s, CH
3), 3.94 (2H, t,
J = 5.0 Hz, CH
2-N), 4.09 (2H, qd,
J = 7.1 Hz, CH
2), 4.19 (2H, t,
J = 5.0 Hz, CH
2-O), 4.45 (2H, s, CH
2CO), 5.29 (1H, s, H5Ura), 7.10 (1H, s,
J = 7.5 Hz, HPh
2CO), 7.20 (1H, t,
J = 8.4 Hz, HPh2CO), 7.28 (1H, dd,
J = 7.4 and 1.7 Hz, HPh
2CO), 7.34–7.47 (2H, m, HPh
2CO), 7.51 (1H, dt,
J = 8.0 and 1.7 Hz, HPh
2CO), 7.58 (1H, t,
J = 7.3 Hz, HPh
2CO), 7.64–7.66 (2H, m, HPh
2CO).
13C-NMR (DMSO-d
6): 14.0, 19.4, 41.56, 44.2, 60.9, 65.7, 100.2, 112.7, 121.3, 128.5, 128.6, 128.8, 129.2, 131.2, 133.6, 136.5, 151.2, 153.4, 155.2, 160.5, 167.8, 195.5 (see
Supplementary Materials).
Ethyl ester of [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (4b). Purified by crystallization from an ethyl acetate-hexane mixture (2:1) in 77% yield. Mp 118–119 °C, Rf 0.57 (ethyl acetate:1,2-dichloroethane, 1:1).1H-NMR (DMSO-d6): 1.16 (3H, t, J = 7.1 Hz, CH3), 1.63 (3H, s, CH3), 3.86 (2H, t, J = 5 Hz, CH2), 4.10 (2H, t, J = 7.1 Hz, CH2), 4.19 (2H, qd, J = 5.0 Hz, CH2), 4.46 (2H, s, CH2CO), 6.98 (1H, d, J = 1.1 Hz, H6Thy), 7.10 (1H, t, J = 7.5 Hz, HPh2CO), 7.21 (1H, t, J = 8.4 Hz, HPh2CO), 7.30 (1H, dd, J = 7.5 and 1.7 Hz, HPh2CO), 7.45–7.49 (2H, m, HPh2CO), 7.52 (1H, dt, J = 8.0 and 1.7 Hz, HPh2CO), 7.59 (1H, t, J = 7.4 Hz, HPh2CO), 7.65–7.67 (2H, m, HPh2CO). 13C-NMR (DMSO-d6): 12.4, 14.0, 41.8, 48.0, 60.9, 65.6, 107.1, 112.9, 121.2, 128.5, 128.9, 129.1, 132.0, 133.4, 136.8, 140.8, 150.4, 155.3, 162.4, 167.8, 195.3.
Ethyl ester of [2,6-dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (4c). Purified by crystallization from an ethyl acetate-hexane mixture (2:1) in 84% yield. Mp 152–153 °C, Rf 0.67 (ethyl acetate:1,2-dichloroethane, 1:1).1H-NMR (DMSO-d6): 1.16 (3H, t, J = 7.0 Hz, CH3), 2.28 (6H, t, CH3), 3.72 (2H, t, J = 4.9 Hz, N-CH2), 4.09 (2H, t, J = 7.0 Hz, O-CH2), 4.18 (2H, qd, J = 5.1 Hz, CH2), 4.43 (2H, s, CH2CO), 5.32 (1H, d, J = 7.9 Hz, H5Ura), 6.94 (1H, d, J = 8.0 Hz, H-3”), 7.22–7.34 (4H, m, H-5”, H-2‘, H-4‘, H-6′), 7.55 (1H, dd, J = 8.9 and 2.7 Hz, H-6”). 13C-NMR (DMSO-d6): 14.0, 20.7, 41.5, 48.1, 61.0, 66.1, 99.4, 114.9, 125.1, 127.0, 128.1, 130.6, 131.3, 125.2, 136.5, 138.0, 144.4, 150.6, 154.0, 161.5, 167.6, 193.9.
Ethyl ester of [2,6-dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (4d). Purified by crystallization from an ethyl acetate-hexane mixture (2:1) in 87% yield. Mp 153-154 °C, Rf 0.73 (ethyl acetate:1,2-dichloroethane, 1:1).1H- NMR (DMSO-d6): 1.16 (3H, t, J = 5.0 Hz, CH3), 2.27 (3H, s, CH3), 2.29 (6H, s, CH3), 3.86 (2H, t, J = 5.0 Hz, N–CH2), 4.09 (2H, qd, J = 7.2 Hz, CH2), 4.20 (2H, t, J = 5.0 Hz, O–CH2), 4.44 (2H, s, CH2CO), 6.98 (1H, s, H-3”), 7.24–7.31 (5H, m, H-5”, H-2′, H-4′, H-6′, H6Ura), 7.54 (1H, dd, J = 8.9 и 2.6 Hz, H-6”). 13C-NMR (DMSO-d6): 12.2, 13.9, 20.6, 41.6, 47.9, 60.9, 66.1, 107.0, 115.1, 125.0, 126.9, 128.0, 130.6, 131.2, 135.1, 136.2, 137.9, 140.7, 150.3, 154.0, 162.2, 167.6, 193.7.
Ethyl ester of [2,6-dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (4e). Was obtain as an oil in 74% yield and used in the subsequent hydrolysis without further purification. Rf 0.64 (ethyl acetate:1,2-dichloroethan, 1:1).
Ethyl ester of [2,6-dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-bromophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (4f). Purified by crystallization from an ethyl acetate-hexane mixture (2:1) in 89% yield. Mp 152–153 °C, Rf 0.66 (ethyl acetate:1,2-dichloroethanw, 1:1).1H-NMR (DMSO-d6): 1.16 (3H, t, J = 7.1 Hz, CH3), 2.23 (6H, s, CH3), 3.87 (2H, t, J = 4.8 Hz, N-CH2), 4.09 (2H, qd, J = 7.1 Hz, CH2), 4.20 (2H, t, J = 5.0 Hz, O–CH2), 4.42 (2H, s, CH2CO), 5.31 (1H, d, J = 8.0 Hz, H5Ura), 6.93 (1H, d, J = 7.9 Hz, H-3”), 7.18 (1H, d, J = 8.0 Hz, H6Ura), 7.26 (1H, s, H-4′), 7.27 (2H, s, H-2′, H-6′), 7.44 (1H, d, J = 2.5 Hz, H-3′), 7.67 (1H, dd, J = 8.9 and 2.6 Hz, H-6”); 13C-NMR (DMSO-d6): 14.0, 20.7, 41.5, 48.1, 61.0, 66.0, 99.4, 112.7, 115.4, 127.0, 130.9, 131.0, 134.2, 135.2, 136.5, 138.0, 144.4, 150.6, 154.5, 161.5, 167.6, 193.8.
Ethyl ester of [2,6-dioxo-3-[(2-[2-(3,5-dichlorobenzoyl)-4-bromophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (4g). Purified by crystallization from an ethyl acetate-hexane mixture (2:1) in 86% yield. Mp 162.5–165.5 °C, Rf 0.70 (ethyl acetate:1,2-dichloroethane, 1:1).1H-NMR (DMSO-d6): 1.16 (3H, t, J = 7.1 Hz, CH3), 3.92 (2H, t, J = 4.9 Hz, N-CH2), 4.10 (2H, qd, J = 7.2 Hz, CH2), 4.22 (2H, t, J = 5.0 Hz, O–CH2), 4.46 (2H, s, CH2CO), 5.41 (1H, d, J = 7.9 Hz, H5Ura), 7.18 (1H, d, J = 7.9 Hz, H6Ura), 7.21 (1H, d, J = 9.0 Hz, H-5”), 7.55 (1H, d, J = 2.4 Hz, H-4′), 7.57 (2H, d, J = 1.9 Hz, H-2′, H-6′), 7.73 (1H, dd, J = 8.9 and 2.6 Hz, H-6”), 7.85 (1H, t, J = 1.7 Hz, H-3”). 13C-NMR (DMSO-d6): 13.9, 41.4, 47.9, 60.9, 65.9, 99.3, 112.7, 115.4, 127.4, 128.9, 131.4, 132.8, 134.6, 135.1, 139.3, 144.4, 150.5, 154.6, 161.3, 167.5, 191.2.
3.2.2. General Method for the Synthesis of [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acids 5a–5g
The corresponding ethyl ester of [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl)]-3,6-dihydro-pyrimidin-1(2H)-yl]acetic acid 4a–4g (1.75 mmol) was dissolved in ethanol (50 mL) then LiOH (0.25 g; 10.44 mmol) and water (30 mL) were added. The resulting mixture was stirred at room temperature for 24 h. Ethanol was evaporated under reduced pressure, 50 mL of water was added to the residue, acidified with 6% aqueous hydrochloric acid, and refrigerated overnight. The precipitate was filtered off, washed on the filter with a large amount of water and dried. After crystallization from an ethyl acetate-hexane mixture, the yield of the desired acids 5a–5g was in the range of 80–94%.
[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5a). Purified by crystallization from an ethyl acetate-hexane mixture (3:1) in 90% yield. Mp 194.5–196 °C, Rf 0.63 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 1.89 (3H, s, CH3), 3.93 (2H, t, J = 5.0 Hz, CH2), 4.20 (2H, t, J = 5.1 Hz, CH2), 4.36 (2H, s, CH2CO), 5.30 (1H, d, J = 0.7 Hz, H5Ura), 7.10 (9H, dt, J = 7.5 and 0.8 Hz, HPh2CO), 7.20 (1H, d, J = 8.4 Hz, HPh2CO), 7.28 (1H, dd, J = 7.4 and 1.6 Hz, HPh2CO), 7.43–7.47 (2H, m, HPh2CO), 7.49–7.54 (1H, m, HPh2CO), 7.58 (1H, dt, J = 7.3 and 1.3 Hz, HPh2CO), 7.64–7.66 (1H, m, HPh2CO), 12.86 (1H, bs, COOH). 13C-NMR (DMSO-d6): 19.3, 41.5, 44.1, 65.7, 100.2, 112.8, 121.2, 128.4, 128.6, 128.8, 129.1, 131.7, 133.5, 136.5, 151.2, 155.2, 157.1, 160.5, 169.0, 195.5.
[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5b). Purified by crystallization from an ethyl acetate-hexane mixture (3:1) in 87% yield. Mp 195.5–196.5 °C, Rf 0.6 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 1.63 (3H, d, J = 0.8 Hz, CH3), 3.85 (2H, t, J = 5.0 Hz, CH2-N), 4.19 (2H, t, J = 5.0 Hz, CH2-O), 4.37 (2H, s, CH2CO), 6.97 (1H, d, J = 1.1 Hz, HPh2CO), 7.10 (1H, t, J = 7.4 Hz, HPh2CO), 7.21 (1H, d, J = 8.4 Hz, HPh2CO), 7.30 (1H, dd, J = 7.5 and 1.7 Hz, HPh2CO), 7.47 (2H, t, J = 7.5 Hz, HPh2CO), 7.52 (1H, dt, J = 8.0 and 1.7 Hz, HPh2CO), 7.60 (1H, t, J = 7.4 Hz, HPh2CO), 7.65–7.67 (1H, t, HPh2CO, H6Ura), 12.86 (1H, bs, COOH). 13C-NMR (DMSO-d6): 12.3, 41.7, 47.9, 65.6, 107.0, 112.9, 121.1, 128.4, 128.8, 129.0, 132.0, 133.3, 136.7, 140.5, 150.4, 155.3, 162.3, 169.0, 195.2.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5c). Purified by crystallization from an ethyl acetate-hexane (3:1) mixture in 85% yield. Mp 215–216 °C, Rf 0.57 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 2.28 (6H, s, CH3), 3.87 (2H, t, J = 4.9 Hz, N-CH2), 4.18 (2H, t, J = 5.1 Hz, O-CH2), 4.34 (2H, s, CH2CO), 5.32 (1H, d, J = 7.9 Hz, H5Ura), 6.94 (1H, d, J = 7.9 Hz, H-5”), 7.22–7.27 (4H, m, H-2′, H-4′, H-6′, H6Ura), 7.34 (1H, d, J = 2.6 Hz, H-3”), 7.55 (1H, dd, J = 8.9 and 2.8 Hz, H-6”), 12.88 (1H, bs, COOH). 13C-NMR (DMSO-d6): 20.6, 41.3, 48.0, 66.0, 99.3, 114.9, 125.0, 126.9, 128.0, 130.5, 131.2, 135.1, 136.4, 137.9, 144.2, 150.5, 153.9, 161.5, 168.9, 193.8.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5d). Purified by crystallization from an ethyl acetate-hexane mixture (3:1) in 94% yield. Mp 238–239 °C, Rf 0.6 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 1.62 (3H, s, CH3), 2.28 (6H, s, CH3), 3.86 (2H, t, J = 5.0 Hz, N–CH2), 4.20 (2H, t, J = 5.0 Hz, O–CH2), 4.35 (2H, s, CH2CO), 6.97 (1H, d, J = 7.9 Hz, H-5”), 7.22–7.27 (4H, m, H-2′, H-4′, H-6′, H6Ura), 7.31 (1H, d, J = 2.7 Hz, H-3”), 7.55 (1H, dd, J = 8.9 and 2.7 Hz, H-6), 12.87 (1H, bs, COOH). 13C-NMR (DMSO-d6): 12.2, 20.6, 41.6, 47.8, 66.1, 107.0, 115.1, 125.0, 126.9, 127.9, 130.5, 131.1, 135.1, 136.2, 137.8, 140.5, 150.4, 153.9, 162.2, 169.0, 193.7.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5e). Purified by crystallization from an ethyl acetate-hexane mixture (3:1) in 80% yield. Mp 213–214.5 °C, Rf 0.56 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 1.87 (3H, s, CH3), 2.26 (6H, c, CH3), 3.94 (2H, t, J = 4.9 Hz, N–CH2), 4.20 (2H, t, J = 5.0 Hz, O–CH2), 4.36 (2H, s, CH2CO), 5.25 (1H, s, H5Ura), 7.22 (1H, s, H-4′), 7.25 (3H, s, H-2′, H-6′), 7.32 (1H, d, J = 2.6 Hz, H-3”), 7.54 (1H, dd, J = 8.9 and 2.7 Hz, H-6”), 12.87 (1H, bs, COOH). 13C-NMR (DMSO-d6): 19.3, 20.6, 41.4, 44.0, 66.2, 100.0, 114.8, 125.1, 126.9, 127.7, 130.7, 131.0, 135.3, 136.0, 138.0, 151.2, 153.0, 153.9, 160.4, 168.9, 194.0.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-bromophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5f). Purified by crystallization from an ethyl acetate-hexane mixture (3:1) in 81% yield. Mp 224.5–225.5 °C, Rf 0.47 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 2.28 (6H, s, CH3), 3.87 (2H, t, J = 5.0 Hz, N-CH2), 4.18 (2H, t, J = 5.0 Hz, O-CH2), 4.34 (2H, s, CH2CO), 5.31 (1H, d, J = 7.8 Hz, H5Ura), 6.93 (1H, d, J = 8.0 Hz, H-5”), 7.18 (1H, d, J = 9.0 Hz, H6Ura), 7.27 (3H, м, H-2′, H-4′, H-6′), 7.45 (1H, d, J = 2.6 Hz, H-3”), 7.67 (1H, dd, J = 8.9 and 2.6 Hz, H-6”), 12.89 (1H, bs, COOH). 13C-NMR (DMSO-d6): 20.6, 41.3, 48.0, 66.0, 99.3, 112.6, 115.3, 126.9, 130.8, 130.9, 134.1, 135.1, 136.4, 137.9, 144.2, 150.5, 154.4, 161.5, 168.9, 193.7.
[2,6-Dioxo-3-[(2-[2-(3,5-dichlorobenzoyl)-4-bromophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]carboxylic acid (5g). Purified by crystallization from an ethyl acetate-hexane mixture (3:1) in 86% yield. Mp 212–213 °C, Rf 0.51 (ethyl acetate: isopropanol: 40% aq. NH4OH, 6:9:5).1H-NMR (DMSO-d6): 3.92 (2H, t, J = 5.0 Hz, N-CH2), 4.18 (2H, t, J = 5.0 Hz, O-CH2), 4.38 (2H, s, CH2CO), 5.40 (1H, d, J = 7.8 Hz, H5Ura), 7.16 (1H, d, J = 7.8 Hz, H-5”), 7.21 (1H, d, J = 8.9 Hz, H6Ura), 7.55 (1H, d, J = 2.6 Hz, H-4′), 7.57 (2H, d, J = 2.0 Hz, H-2′, H-6′), 7.73 (1H, dd, J = 8.9 and 2.6 Hz, H-6”), 7.85 (1H, t, J = 2.0 Hz, H-3”), 12.89 (1H, bs, COOH). 13C-NMR (DMSO-d6): 41.4, 47.9, 65.9, 99.3, 112.7, 115.4, 127.4, 128.9, 131.4, 132.8, 134.6, 135.1, 139.3, 144.2, 150.5, 154.6, 161.4, 168.8, 191.2.
3.2.3. General Method for the Synthesis of ACV Derivatives
A mixture of the corresponding [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl)]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid (0.5 mmol) and ACV (0.5 mmol) was twice evaporated in DMF, then dissolved in DMF (5 mL) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.2 eq) and dimethyl-aminopyridine (0.5 eq) were added. The reaction mixture was allowed to mix for 16 h at room temperature. The progress of the reaction was monitored by TLC. The solvent was then evaporated and the residue was purified by column chromatography on silica gel eluting with a 9:1 chloroform-methanol mixture. The yield of the target products was 26–39%.
[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of ACV (2a). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 33% yield. Rf 0.57 (chloroform:methanol, 95:5). 1H-NMR (CD3OD:CDCl3): 1.97 (3H, s, CH3), 3.88-3.91 (2H, m, CH2O), 4.04–4.07 (2H, m, CH2N), 4.24–4.37 (4H, m, 2 × CH2CH2C=O), 4.58 (2H, s, NCH2C=O), 5.29 (1H, d, H5Ura), 5.64 (2H, s, OCH2N), 7.06–7.12 (2H, m, Ph), 7.24–7.28 (1H, d, Ph), 7.40–7.52 (3H, m, Ph), 7.54–7.60 (1H, m, Ph), 7.73–7.76 (2H, d, Ph), 9.02 (1H, s, H8). 13C-NMR (DMSO-d6): 19.9, 41.9, 44.6, 64.3, 66.1, 66.7, 72.3, 100.6, 113.25, 117.0, 121.7, 129.0, 129.1, 129.2, 129.7, 132.3, 134.1, 136.9, 138.0, 151.6, 151.9, 153.9, 154.6, 155.6, 155.6, 157.2, 161.0, 168.3, 196. HRMS: m/z [M + H]+ calcd for C30H29N7O8: 616.2150, found: 616.2136.
[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of ACV (2b). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 23% yield. Rf 0.62 (chloroform:methanol, 95:5). 1H-NMR (CD3OD:CDCl3): 1.72 (3H, s, CH3), 3.70–3.78 (2H, m, CH2O), 3.91–3.94 (2H, m, CH2N), 4.20–4.30 (4H, m, 2 × CH2CH2C=O), 4.61 (2H, s, NCH2C=O), 5.49 (2H, s, OCH2N), 6.80–6.81 (1H, s, H6Ura), 7.03-7.10 (2H, m, Ph), 7.30–7.33 (1H, d, J = 12Hz, Ph), 7.44–7.50 (3H, m, Ph), 7.57–7.60 (1H, m, Ph), 7.76-7.79 (2H, d, Ph), 8.17 (1H, s, H8). 13C-NMR (DMSO-d6): 19.9, 41.9, 44.6, 64.3, 66.1, 66.8, 72.3, 100.6, 113.3, 117.0, 121.7, 129.0, 129.1, 129.2, 129.7, 132.3, 134.1, 136.9, 138.0, 151.6, 151.9, 153.9, 154.5, 155.6, 157.2, 160.9, 168.3, 196.0 HRMS: m/z [M + H]+ calcd for C30H29N7O8: 616.2150, found: 616.2128.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]-acetate of ACV (2c). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 19% yield. Rf 0.65 (chloroform:methanol, 95:5). 1H-NMR (CD3OD): 2.29 (6H, s, 2 × CH3), 3.77-3.78 (2H, m, CH2O), 3.90–3.91 (2H, m, CH2N), 4.16–4.22 (4H, m, 2 × CH2CH2C=O), 4.50 (2H, s, NCH2C=O), 5.26–5.28 (1H, d, J = 8Hz, H5Ura), 5.47 (2H, s, OCH2N), 6.79–6.82 (1H, d, J = 12Hz, H6Ura), 7.07–7.10 (1H, d, J = 12Hz, Ph), 7.21–7.24 (2H, m, Ph), 7.30 (2H, m, Ph), 7.45–7.42 (1H, m, Ph), 8.23 (1H, s, H8). 13C-NMR (CD3OD): 19.9, 31.6, 41.4, 60.9, 63.9, 66.2, 67.3, 70.2, 72.3, 72.9, 99.5, 114.3, 126.2, 127.2, 128.3, 130.8, 131.8, 135.3, 136.5, 144.7, 151.0, 154.3, 154.9, 156.7, 162.9, 168.0, 195.1. HRMS: m/z [M − H]− calcd for C31H30ClN7O8: 662.1761, found: 662.1763.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of ACV (2d). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 38% yield. Rf 0.59 (chloroform:methanol, 95:5). 1H-NMR (DMSO-d6): 1.88 (3H, s, CH3), 2.26 (6H, s, 2 × CH3), 3.66–3.69 (2H, m, CH2O), 3.94–3.96 (2H, m, CH2N), 4.15–4.22 (4H, m, 2 × CH2CH2C=O), 4.25 (2H, s, NCH2C=O), 5.36 (2H, s, OCH2N), 6.58 (2H, s, NH2), 7.03 (1H, d, H6 Ura), 7.20–7.37 (5H, m, Ph), 7.53–7.57 (1H, m, Ph), 7.85 (1H, s, H8), 10.70 (1H, s, NH). 13C-NMR (DMSO-d6): 19.9, 21.1, 41.8, 44.6, 64.3, 66.6, 66.8, 70.3, 72.3, 100.5, 115.3, 116.8, 125.6, 127.5, 128.2, 131.2, 135.9, 136.5, 138.1, 138.6, 151.6, 151.9, 153.9, 154.4, 157.2, 160.9, 168.2, 194.5. HRMS: m/z [M + H]+ calcd for C32H32ClN7O8: 678.2074, found: 678.2073.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of ACV (2e). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 14% yield. Rf 0.6 (chloroform:methanol, 95:5). 1H-NMR (DMSO-d6): 1.83 (3H, s, CH3), 2.21 (6H, s, 2 × CH3), 3.66–3.67 (2H, m, CH2O), 3.88–3.91 (2H, m, CH2N), 4.12–4.17 (4H, m, 2 × CH2CH2C=O), 4.40 (2H, m, NCH2C=O), 5.22 (1H, d, H5Ura), 5.36 (2H, s, OCH2N), 6.75 (2H, s, NH2), 7.19–7.22 (5H, m, Ph), 7.48–7.52 (1H, m, Ph), 8.17 (1H, s, H8), 10.94 (1H, s, NH). 13C-NMR (DMSO-d6): 12.7, 21.2, 42.0, 48.3, 64.3, 66.6, 66.8, 70.3, 72.4, 107.5, 115.6, 125.6, 127.4, 128.5, 131.1, 131.7, 135.7, 136.7, 138.4, 141.3, 150.8, 154.5, 162.7, 168.2, 194.2. HRMS: m/z [M + H]+ calcd for C32H32ClN7O8: 678.2074, found: 678.2076.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-bromophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]acetate of ACV (2f). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 22% yield. Rf 0.64 (chloroform:methanol, 95:5). 1H-NMR (CD3OD): 2.34 (6H, s, 2 × CH3), 3.76–3.79 (2H, m, CH2O), 3.95–3.97 (2H, m, CH2N), 4.23–4.26 (4H, m, 2 × CH2CH2C=O), 4.55 (2H, s, NCH2C=O), 5.30-5.33 (1H, d, J = 12 Hz, H5Ura), 5.45 (2H, s, OCH2N), 6.85-6.88 (1H, d, J = 12 Hz, H-6), 7.07–7.10 (1H, d, J = 12Hz, Ph), 7.36 (1H, m, Ph), 7.39–7.40 (3H, m, Ph), 7.61-7.65 (1H, m, Ph), 7.82 (1H, s, H8). 13C-NMR (DMSO-d6): 21.1, 41.8, 48.6, 64.4, 66.5, 66.8, 70,3, 72.3, 99.8, 113.2, 115.9, 117.0, 127.4, 131.3, 131.4, 134.7, 135.7, 136.9, 138.1, 138.5, 144.9, 151.0, 151.9, 154.5, 154.9, 157.2, 161.9, 168.2, 194.3. HRMS: m/z [M − H]− calcd for C31H30BrN7O8: 706.1255, found: 706.1261.
[2,6-Dioxo-3-[(2-[2-(3,5-dichlorobenzoyl)-4-bromophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]acetate of ACV (2g). Purified on a silica gel column using chloroform:methanol (9:1) as eluent in 13% yield. Rf 0.56 (chloroform:methanol, 95:5). 1H-NMR (CD3OD): 3.75–3.78 (2H, m, CH2O), 3.94–3.96 (2H, m, CH2N), 4.22–4.24 (4H, m, 2xCH2CH2C=O), 4.55 (2H, s, NCH2C=O), 5.40–5.43 (1H, d, J=12Hz, H5Ura), 5.45 (2H, s, OCH2N), 7.00–7.02 (1H, d, J = 8Hz, H6Ura), 7.07–7.10 (1H, d, J=12Hz, Ph), 7.45 (1H, m, Ph), 7.57–7.58 (2H, m, Ph), 7.63–7.64 (2H, m, Ph), 7.82 (1H, s, H8). 13C-NMR (DMSO-d6): 14.4, 22.5, 23.1, 41.8, 64.4, 66.4, 72.3, 79.65, 99.8, 113.2, 115.6, 116.9, 128.0, 129.4, 132.0, 133.4, 135.2, 135.7, 138.0, 139.8, 145.0, 151.0, 151.9, 154.7, 155.09, 157.4, 161.9, 168.1, 191.8. HRMS: m/z [M − H]− calcd for C29H24BrCl2N7O8: 746.0163, found: 746.0177.
3.2.4. General Method for the Synthesis of 9-(4′-hydroxy-2′cyclopenten-1′-yl)adenine Derivatives 6a–6d
A mixture of 9-(4′-hydroxy-2′-cyclopenten-1′-yl)adenine (0.5 mmol) and the corresponding [2,6-dioxo-3-[(2-benzoylphenoxy)ethyl)]-3,6-dihydropyrimidine-1(2H)-yl]acetic acid 5a–5d (0.5 mmol) was twice evaporated from DMF, then again dissolved in DMF (5 mL) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.6 mmol) and dimethylaminopyridine (0.25 mmol) were added. The mixture was stirred for 16 h at room temperature. The solvent was evaporated in vacuo, the residue was purified by silica gel column chromatography, eluting with the chloroform: methanol system (95:5). The yield of the desired esters 6a–6g was in the range of 56–84%.
9-(4′-[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetyl-2′cyclo-penten-1′-yl)adenine (6a). Purified on a silica gel column using chloroform: methanol (98:2) as eluent in 62% yield. Rf 0.53 (chloroform:methanol, 95:5). 1H-NMR (CDCl3): 1.94 (3H, s, CH3), 1.98–2.02 (1H, m, H5′a), 3.04–3.14 (1H, m, 5′Hb), 4.01–4.04 (2H, m, CH2-N), 4.24–4.26 (2H, m, CH2-O), 4.57–4.69 (2H, d, J = 3.2 Hz, CH2CO), 5.25 (1H, s, H5Ura), 5.68–5.71 (1H, m, H4′), 5.81–5.83 (1H, m, H1′), 5.96 (2H, s, NH2), 6.18–6.21 (1H, m, H3′), 6.32–6.36 (1H, m, H2′), 6.96–6.98 (1H, d, J = 8.1 Hz, HPh2CO), 7.08–7.11 (1H, t, J = 7.9 Hz, HPh2CO), 7.31 (1H, m, HPh2CO), 7.40–7.45 (3H, m, HPh2CO), 7.58–7.60 (1H, m, HPh2CO), 7.77–7.79 (2H, d, J = 7.1 Hz, HPh2CO), 7.84 (1H, s, H8), 8.38 (1H, s, H2). 13C-NMR (CDCl3): 20.3, 38.4, 42.0, 44.8, 56.7, 66.0, 70.6, 78.2, 101.5, 112.3, 121.6, 128.5, 129.1, 129.9, 131.6, 133.6, 134.8, 135.0, 138.7, 152.7, 155.4, 161.1, 167.4.
9-(4′-[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetyl-2′cyclo-penten-1′-yl)adenine (6b). Purified on a silica gel column using chloroform:methanol (98:2) as eluent in 84% yield. Rf 0.55 (chloroform:methanol, 95:5). 1H-NMR (CDCl3): 1.74 (3H, s, CH3), 1.97–2.03 (1H, m, H5′a), 3.07–3.12 (1H, m, 5′Hb), 3.91–3.96 (2H, m, CH2-N), 4.19–4.21 (2H, m, CH2-O), 4.60–4.72 (2H, d, J = 1.3 Hz, CH2CO), 5.68–5.70 (1H, m, H4′), 5.80–5.82 (1H, m, H1′), 5.86 (2H, s, NH2), 6.18–6.21 (1H, m, H3′), 6.33–6.35 (1H, m, H2′), 6.75 (1H, s, H6Ura), 6.94–6.96 (1H, d, J = 8.3 Hz, HPh2CO), 7.08–7.11 (1H, t, J = 7.4 Hz, HPh2CO), 7.35 (1H, m, HPh2CO), 7.44–7.50 (3H, m, HPh2CO), 7.57–7.60 (1H, m, HPh2CO), 7.82–7.84 (3H, m, HPh2CO,H8), 8.39 (1H, s, H2). 13C-NMR (CDCl3): 12.6, 38.4, 42.2, 48.9, 56.7, 66.3, 70.6, 78.2, 109.2, 112.3, 119.7, 121.3, 128.4, 129.9, 129.9, 132.2, 133.3, 135.1, 149.7, 151.0, 152.7, 155.3, 155.8, 163.0, 167.4, 195.4.
9-(4′-[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]acetyl-2′cyclopenten-1′-yl)adenine (6c). Purified on a silica gel column using chloroform:methanol (98:2) as eluent in 58% yield. Rf 0.61 (chloroform: methanol, 95:5). 1H-NMR (CDCl3): 1.99–2.02 (1H, m, H5′a), 2.37 (6H, s, 2 × CH3), 3.05–3.12 (1H, m, 5′Hb), 3.92–3.95 (2H, m, CH2-N), 4.15–4.18 (2H, m, CH2-O), 4.58–4.70 (2H, d, J = 3.0 Hz, CH2CO), 5.33–5.35 (1H, d, 7.9 Hz, H5Ura), 5.70–5.72 (1H, m, H4′), 5.80–5.83 (1H, m, H1′), 5.85 (2H, s, NH2), 6.21–6.22 (1H, m, H3′), 6.35 (1H, m, H2′), 6.60–6.63 (1H, d, 7.9 Hz, H6Ura), 6.87–6.90 (1H, d, J = 8.8 Hz, HPh2CO), 7.27–7.33 (3H, m, HPh2CO), 7.34–7.40 (3H, m, HPh2CO), 7.84 (1H, s, HPh2CO) 7.82–7.84 (3H, m, HPh2CO,H8), 8.39 (1H, s, H2). 13C-NMR (CDCl3): 21.2, 38.4, 41.9, 49.0, 56.7, 66.8, 70.6, 78.3, 100.8, 113.7, 126.8, 127.5, 129.4, 131.5, 134.8, 135.0, 135.5, 137.2, 138.5, 138.7, 143.8, 151.1, 152.8, 154.1, 155.2, 161.9, 167.2, 194.4.
9-(4′-[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-6-methyl-3,6-dihydro-pyrimidine-1(2H)-yl]acetyl-2′cyclopenten-1′-yl)adenine (6d). Purified on a silica gel column using chloroform:methanol (98:2) as eluent with 56% yield. Rf 0.58 (chloroform:methanol, 95:5). 1H-NMR (CDCl3): 1.74 (3H, s, CH3), 2.01–2.06 (1H, m, H5′a), 2.37 (6H, s, 2 × CH3), 3.05–3.08 (1H, m, 5′Hb), 3.94–3.96 (2H, m, CH2-N), 4.18–4.19 (2H, m, CH2-O), 4.65–4.68 (2H, d, J = 7.4 Hz, CH2CO), 5.70–5.72 (1H, m, H4′), 5.80–5.82 (1H, m, H1′), 6.20–6.23 (1H, m, H3′), 6.38–6.40 (1H, m, H2′), 6.76 (2H, s, NH2), 6.89–6.92 (1H, d, J = 8.8 Hz, H6Ura), 7.26–7.29 (3H, m, HPh2CO), 7.40–7.41 (3H, m, HPh2CO), 7.94 (1H, s, H8), 8.37 (1H, s, H2). 13C-NMR (CDCl3): 12.5, 21.2, 38.4, 42.2, 48.8, 57.1, 66.9, 70.6, 78.1, 109.3, 113.9, 119.3, 126.5, 127.7, 129.3, 131.5, 134.4, 135.5 x 2, 138.4, 139.7, 140.4, 149.3, 149.6, 151.1, 153.9, 154.3, 163.0, 167.4, 194.5.
3.2.5. General Method for the Synthesis of 5′-noraristeromycin Derivatives 3a–3d
To a solution of the corresponding 9-(4′-hydroxy-2′-cyclopenten-1′-yl)adenine derivative 6a–3d (0.3 mmol) in a (10:1) dioxane:water mixture (10 mL), osmium tetroxide (0.01 mmol) and N-methylmorpholine oxide (2 mmol) were added. The reaction mixture was stirred/ for 3 h at the room temperature. The progress of the reaction was monitored by TLC. Then the solvents were evaporated in vacuo, the residue was purified by silica gel column chromatography, eluting with the chloroform: methanol system (95: 5). The yields of target esters 3a–3g were in the range of 43–65%.
[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-6-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of 5′-nor-aristeromycin (3a). Purified on a silica gel column using chloroform:methanol (95:5) as eluent in 60% yield. Rf 0.52 (chloroform: methanol, 9:1). 1H-NMR (CDCl3:CD3OD): 1.91 (3H, s, CH3), 2.16–2.24 (1H, m, H5′a), 2.92–3.03 (1H, m, 5Hb), 3.99–4.02 (2H, m, CH2-N), 4.14–4.15 (1H, m, H4′), 4.20–4.23 (2H, m, CH2-O), 4.46–4.50 (1H, m, H1′), 4.56–4.61(2H, m, CH2CO), 4.79–4.82 (1H, m, H3′), 5.06–5.09 (1H, m, H2′), 5.24 (1H, s, H5Ura), 6.96–6.99 (1H, m, HPh2CO), 7.03–7.08 (1H, m, HPh2CO), 7.25–7.36 (1H, d, J = 5.8 Hz, HPh2CO), 7.40–7.43 (3H, d, J = 7.9 Hz, HPh2CO), 7.52–7.55 (1H, m, HPh2CO) 7.73–7.75 (2H, d, J = 7.2 Hz, HPh2CO), 7.99 (1H, s, H8), 8.25 (1H, s, H2). 13C-NMR (CDCl3:CD3OD): 20.1, 33.1, 42.0, 44.8, 59.1, 65.7, 74.3, 75.6, 100.9, 112.3, 121.3, 128.5, 129.0, 129.9, 131.6, 131.8, 133.8, 136.7, 139.6, 151.6, 152.0, 152.1, 155.5, 161.8, 167.3. HRMS: m/z [M + nH]+ calcd for C32H31N7O8: 642.2307, found: 642.2292; m/z[M + nNa]+ calcd for C32H31N7O8: 664.2126, found: 664.2112.
[2,6-Dioxo-3-[(2-benzoylphenoxy)ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of 5′-nor-aristeromycin (3b). Purified on a silica gel column using chloroform:methanol (95:5) as eluent in 43% yield. Rf 0.56 (chloroform:methanol, 9:1). 1H-NMR (CDCl3:CD3OD): 1.65 (3H, s, CH3), 2.05–2.12 (1H, m, H5′a), 2.69–2.78 (1H, m, 5′Hb), 3.85–3.88 (2H, m, CH2-N), 3.95-3.96 (1H, m, H4′), 4.19–4.22 (2H, t, J = 4.9 Hz, CH2-O), 4.49–4.52 (1H, m, H3′), 4.55–4.59 (2H, m, CH2CO),4.73–4.76 (1H, m, H2′), 4.84–4.86 (1H, m, H1′), 5.20–5.22 (1H, d, J = 6.6 Hz, OH), 5.31–5.33 (1H, d, J = 4.2 Hz, OH), 7.02 (1H, s, H5Ura), 7.10–7.18 (1H, m, HPh2CO), 7.02–7.07 (1H, m, HPh2CO), 7.30–7.33 (1H, m, HPh2CO), 7.42–7.47 (3H, m, HPh2CO), 7.61–7.68 (3H, m, HPh2CO), 8.13–8.15 (2H, d, J = 5.6 Hz, H8 and H2). 13C-NMR (CDCl3:CD3OD): 12.3, 33.1, 42.2, 59.1, 65.1, 70.3, 74.2, 109.0, 112.4, 121.3, 128.4, 129.9, 132.3, 133.5, 137.4, 139.8, 140.9, 151.1, 152.0, 155.4, 155.8, 163.4, 167.4, 196.4. HRMS: m/z [M + nH]+ calcd for C32H31N7O8: 642.2307, found: 642.2304; m/z [M + nNa]+ calcd for C32H31N7O8: 664.2126, found: 664.2126.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-3,6-dihydropyrimidine-1(2H)-yl]-acetate of 5′-noraristeromycin (3c). Purified on a silica gel column using chloroform:methanol (95:5) as eluent in 65% yield. Rf 0.49 (chloroform: methanol, 9:1). 1H-NMR (DMSO-d6): 2.07–2.12 (1H, m, H5′a), 2.30 (6H, s, 2 × CH3), 2.69–2.74 (1H, m, 5′Hb), 3.87–3.90 (2H, m, CH2-N), 3.93–3.97 (1H, m, H4′), 4.17–4.19 (2H, m, CH2-O), 4.47–4.56 (3H, m, CH2CO and H3′), 4.73–4.76 (1H, m, H2′), 4.84–4.88 (1H, m, H1′), 5.20–5.23 (1H, m, OH), 5.32–5.36 (2H, m, OH and H5Ura), 6.96–6.99 (1H, d, J = 7.9 Hz, H6Ura), 7.17 (2H, s, NH2), 7.22–7.29 (4H, m, HPh2CO), 7.35 (1H, m, HPh2CO), 7.53–7.57 (1H, m, HPh2CO), 8.13–8.15 (2H, d, J = 6.5, H2 and H8). 13C-NMR (DMSO-d6): 21.2, 33.1, 48.6, 58.4, 66.5, 70.3, 74.1, 74.6, 77.7, 79.6, 99.8, 115.4, 119.9, 125.6, 127.4, 128.6, 131.0, 131.7, 135.7, 136.9, 138.5, 140.6, 144.9, 150.1, 151.0, 152.7, 154.4, 156.5, 162.0, 167.7, 194.4. HRMS: m/z [M + nH]+ calcd for C33H32ClN7O8: 690.2074, found: 690.2053.
[2,6-Dioxo-3-[(2-[2-(3,5-dimethylbenzoyl)-4-chlorophenophenoxy]ethyl]-5-methyl-3,6-dihydropyrimidine-1(2H)-yl]acetate of 5′-noraristeromycin (3d). Purified on a silica gel column using chloroform:methanol (95:5) as eluent with 57% yield. Rf 0.48 (chloroform: methanol, 9:1). 1H-NMR (DMSO-d6): 1.64 (3H, s, CH3), 2.06–2.11 (1H, m, H5′a), 2.29 (6H, s, 2 × CH3), 2.66–2.73 (1H, m, 5′Hb), 3.88–3.89 (2H, m, CH2-N), 3.95–3.97 (1H, m, H4′), 4.20–4.21 (2H, d, J = 4.8 Hz, CH2-O), 4.48–4.53 (3H, m, CH2CO and H3′), 4.73–4.76 (1H, m, H2′), 4.84–4.88 (1H, m, H1′), 5.21–5.23 (1H, d, J = 6.6 Hz, OH), 5.32–5.33 (1H, d, J = 4.3, OH), 7.02 (1H, s, H6Ura), 7.18 (2H, s, NH2), 7.24–7.28 (4H, m, HPh2CO), 7.32–7.33 (1H, d, J = 2.7 Hz, HPh2CO), 7.53–7.57 (1H, m, HPh2CO), 8.13-8.15 (2H, d, J = 7.1 Hz, H2 and H8). 13C-NMR (DMSO-d6): 12.7, 21.2, 33.1, 42.3, 48.4, 58.4, 66.6, 70.3, 74.1, 74.7, 77.7, 107.5, 115.6, 119.7, 125.6, 127.4, 128.5, 131.1, 131.7, 135.7, 136.8, 138.4, 140.6, 141.2, 150.2, 150.9, 152.7, 154.5, 156.5, 162.8, 167.8, 194.2. HRMS: m/z [M + nH]+ calcd for C34H34ClN7O8: 704.2230, found: 704.2217.